» Articles » PMID: 29209982

Adherence to Inhaled Medications and Its Effect on Healthcare Utilization and Costs Among High-Grade Chronic Obstructive Pulmonary Disease Patients

Overview
Date 2017 Dec 7
PMID 29209982
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Adherence to inhaled medication regimens affects chronic obstructive pulmonary disease (COPD) prognosis and quality of life, and reduces the use of healthcare services, resulting in cost savings.

Objectives: To examine the effects of adherence to inhaled medication regimens on healthcare utilization and costs in high-grade COPD patients.

Methods: We performed an observational retrospective cohort study using a longitudinal data set from the Korean Health Insurance Review and Assessment Service (2008-2013) containing healthcare services' information for 50 million beneficiaries. The study population was high-grade COPD patients. "Adherent" was defined as a patient attaining a medication possession ratio (MPR) ≥ 80%. We estimated the effects of adherence on the use of intensive care units (ICUs) and emergency rooms (ERs) using a multivariate logistic regression, and estimated the effects on costs (all-cause and COPD-related) using a generalized linear model, with adjustment for patient sociodemographic characteristics, health status, and comorbidities.

Results: Of 9086 high-grade COPD patients, adherence declined from 34.7 to 22.3% over 4 years. Adherence was inversely associated with use of ICUs and costs, and this association got stronger as the adherence period lengthened. Over the 4-year period, the adherent group had a lower likelihood of using ICUs [odds ratio (OR) = 0.74, 95% confidence interval (CI) 0.60-0.91] than the non-adherent group. Similarly, the adherent group had a 10.4% lower all-cause cost (p < 0.001) and an 11.7% lower COPD-related cost (p < 0.0001) versus the non-adherent group.

Conclusions: Adherence reduces healthcare utilization and costs, so adherence is not only clinically effective but also economically efficient. However, less than one-quarter of this population remained adherent over the 4-year period, suggesting that strategies are needed to improve adherence.

Citing Articles

Adherence to Inhalation Therapy Among COPD Patients: A Cross-Sectional Study in a Tertiary Hospital in Quito, Ecuador.

Izquierdo-Condoy J, Gualpa Alvarez F, Morales-Lapo E, Arias Calvache W, Bermudez Moreira J, Quinga-Chiguano K Int J Chron Obstruct Pulmon Dis. 2025; 20:399-410.

PMID: 40008110 PMC: 11853065. DOI: 10.2147/COPD.S493992.


The association between comprehensive medication review and medication adherence among medicare beneficiaries with chronic obstructive pulmonary disease.

Zhang X, Sim Y, Tsang C, Wang J, Finch C Explor Res Clin Soc Pharm. 2024; 15:100470.

PMID: 39050144 PMC: 11267052. DOI: 10.1016/j.rcsop.2024.100470.


Medication adherence halves COPD patients' hospitalization risk - evidence from Swiss health insurance data.

Bischof A, Cordier J, Vogel J, Geissler A NPJ Prim Care Respir Med. 2024; 34(1):1.

PMID: 38453930 PMC: 10920735. DOI: 10.1038/s41533-024-00361-2.


Development of a daily predictive model for the exacerbation of chronic obstructive pulmonary disease.

Jo Y, Han S, Lee D, Min K, Park S, Yoon H Sci Rep. 2023; 13(1):18669.

PMID: 37907619 PMC: 10618439. DOI: 10.1038/s41598-023-45835-4.


Effect of Broncho-Vaxom (OM-85) on the frequency of chronic obstructive pulmonary disease (COPD) exacerbations.

Choi J, Park Y, An T, Yoo K, Rhee C BMC Pulm Med. 2023; 23(1):378.

PMID: 37805515 PMC: 10559651. DOI: 10.1186/s12890-023-02665-4.


References
1.
Mathers C, Loncar D . Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006; 3(11):e442. PMC: 1664601. DOI: 10.1371/journal.pmed.0030442. View

2.
Jensen H, Godtfredsen N, Lange P, Vestbo J . Potential misclassification of causes of death from COPD. Eur Respir J. 2006; 28(4):781-5. DOI: 10.1183/09031936.06.00152205. View

3.
Jensen M, Fenger-Gron M, Fonager K, Omland O, Vinding A, Georg Hansen J . Chronic obstructive pulmonary disease involves substantial health-care service and social benefit costs. Dan Med J. 2013; 60(1):A4557. View

4.
Kim J, Rhee C, Yoo K, Kim Y, Lee S, Park Y . The health care burden of high grade chronic obstructive pulmonary disease in Korea: analysis of the Korean Health Insurance Review and Assessment Service data. Int J Chron Obstruct Pulmon Dis. 2013; 8:561-8. PMC: 3838475. DOI: 10.2147/COPD.S48577. View

5.
Restrepo R, Alvarez M, Wittnebel L, Sorenson H, Wettstein R, Vines D . Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis. 2008; 3(3):371-84. PMC: 2629978. DOI: 10.2147/copd.s3036. View